ZIOPHARM Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing a portfolio of immuno-oncology therapies to treat patients with cancer. The company develops Sleeping Beauty platform, which is based on the non-viral genetic engineering of immune cells using a transposon/transposase system to engineer T-cells outside of the body for infusion; and Controlled IL-12 to stimulate expression of interleukin 12 or IL-12, a master regular of the immune system, in a controlled manner to focus the patient's immune system to attack cancer cells. Its product candidates include T cell receptor + T therapies to target solid tumors; chimeric antigen receptor + T cell therapies targeting CD19 for hematologic malignancies; and Ad-RTS-hIL-12 plus veledimex, a gene delivery system to regulate production of IL-12 to treat patients with recurrent glioblastoma multiforme in adults. The company has a license agreement with PGEN Therapeutics, Inc.; research and development agreement with The University of Texas MD Anderson Cancer Center; a patent license agreement with the National Cancer Institute; and a cooperative research and development agreement with the National Cancer Institute. ZIOPHARM Oncology, Inc. is headquartered in Boston, Massachusetts.
IPO Year:
Exchange: NASDAQ
Website: ziopharm.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/9/2021 | $3.00 → $2.00 | Market Perform | Raymond James |
| 8/10/2021 | Outperform → Mkt Perform | Raymond James | |
| 8/10/2021 | $3.00 | Outperform → Market Perform | Raymond James |
SC 13G/A - ZIOPHARM ONCOLOGY INC (0001107421) (Subject)
SC 13G/A - ZIOPHARM ONCOLOGY INC (0001107421) (Subject)
SC 13G/A - ZIOPHARM ONCOLOGY INC (0001107421) (Subject)
SC 13G/A - ZIOPHARM ONCOLOGY INC (0001107421) (Subject)
Raymond James reiterated coverage of ZIOPHARM Oncology with a rating of Market Perform and set a new price target of $2.00 from $3.00 previously
Raymond James downgraded ZIOPHARM from Outperform to Mkt Perform
Raymond James downgraded ZIOPHARM Oncology from Outperform to Market Perform and set a new price target of $3.00
Raymond James reiterated coverage of ZIOPHARM Oncology with a rating of Outperform and set a new price target of $4.00 from $5.50 previously
Raymond James initiated coverage of ZIOPHARM Oncology with a rating of Outperform and set a new price target of $5.50
Jefferies Financial Group downgraded ZIOPHARM Oncology from Buy to Hold
Jefferies downgraded ZIOPHARM Oncology from Buy to Hold and set a new price target of $5.00 from $7.00 previously
HC Wainwright resumed coverage of ZIOPHARM Oncology with a rating of Neutral
HC Wainwright & Co. downgraded ZIOPHARM Oncology from Buy to Neutral
Raymond James initiated coverage of ZIOPHARM Oncology with a rating of Outperform and set a new price target of $5.50
HOUSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced financial results for the third quarter ended September 30, 2021 and provided a business update. "I am impressed by the quality and dedication of our team at Ziopharm who all are diligently working to transform our cutting-edge scientific research into meaningful clinical progress. Last quarter we made the decision to restructure the organization and focus our efforts on advancing our differentiated TCR-T library towards the clinic," said Kevin S. Boyle, Sr., Chief Executive Officer at Ziopharm Oncology. "We are making excellent progress to operationa
HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced that it will report financial results for the third quarter ended September 30, 2021 on Monday, November 8, 2021, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 4:30 p.m. ET to provide a corporate update and review the financial results. The conference call can be accessed by dialing 877-451-6152 (United States) or 201-389-0879 (International) with the conference code 13724384. A live webcast may be accessed using the link here, or by visiting the "Investors" section of the Ziopharm website at w
Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles Strong track record of successfully guiding companies and creating shareholder value through disciplined capital management and achievement of milestones Raffaele Baffa MD, Ph.D. appointed Head of Research and Development in addition to Chief Medical Officer Adam Levy, Ph.D., MBA appointed Executive Vice President, Corporate Development and Investor Relations Conference call scheduled for today at 4:30 pm EDT BOSTON and HOUSTON, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced the appointment of Kevin S. Boyl
Accomplished key milestones in groundbreaking TCR-T Library program, including commissioning of Company's manufacturing facility and presentation of favorable preclinical data Closed venture debt financing with Silicon Valley Bank, strengthening balance sheet and extending cash runway into the fourth quarter of 2022 Provided update on CD19 RPM CAR-T trial being conducted by Eden BioCell Conference call scheduled for today at 4:30 pm EDT BOSTON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today provided corporate updates for the second quarter of 2021, ended June 30, 2021. The Company will host a conference call and webcast toda
BOSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP), today announced that management will host a conference call and webcast on Monday, August 9, at 4:30 p.m. EDT to provide a corporate update and discuss financial results for the second quarter ended June 30, 2021. The conference call can be accessed by dialing 877-451-6152 (U.S. and Canada) or 201-389-0879 (International). The passcode for the conference call is 13721210. A live webcast may be accessed using the link here, or by visiting the "Investors" section of the Ziopharm website at www.ziopharm.com. The call will be recorded and available for replay on the Company's website for approximately 90 days aft
– Annual shareholder meeting planned for May 19, 2021 – Company to host conference call today at 4:30 pm ET BOSTON, May 06, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced its financial results for the first quarter ended March 31, 2021 and provided additional corporate updates. The Company will host a conference call and webcast today at 4:30 pm ET. Recent Corporate Highlights and Updates Announced that the infusion of the first patient in the CD19-Specific Rapid Personalized Manufacturing (RPM) CAR-T Phase I Clinical Trial being conducted in Taiwan by the Company's Joint Venture partner, Eden BioCell, occurred in March.P
Heidi Hagen Appointed Interim Chief Executive Officer Replacing Dr. Laurence Cooper; Search for Permanent CEO Initiated Dr. Laurence Cooper Expected to Continue with Company in a Scientific Advisory Role James Huang Appointed Executive Chairman and Board Refreshment Completed FDA IND Clearance Announced for Groundbreaking Library TCR-T Phase I/II Clinical Trial, Targeting Six “Hotspot” Mutations in KRAS and TP53 Further Details Provided on R&D Day on March 11 Including Participation of Dr. Steven Rosenberg, Dr. Carl June, and Dr. Scott Kopetz BOSTON, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (Nasdaq: ZIOP), today announced its financial re
SHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Raffaele Baffa ("Dr. Baffa") has been appointed as the Chief Medical Officer ("CMO") of the Company, responsible for overseeing the global clinical development strategies and operations for the Company's innovative pipeline product candidates. Dr. Baffa will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Dr. Baffa has rich experiences in pharmaceutical industry and research institutes,
Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollment; continue to expect to dose the first patient in 1H 2022 Phase 1/2 IND amended to include four additional TCRs, bringing the total number of evaluable TCRs to 10, further expanding number of eligible patientsIn-house cGMP manufacturing facility is operational to support internal clinical development programsCompany changes name to Alaunos Therapeutics reflecting renewed focus HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), a clinical-stage oncology-focused cell therapy company, today highlighted rec
HOUSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced the presentation of preclinical data highlighting the potential of neoantigen-specific TCR-T cells for the treatment of solid tumors at the Society for Immunotherapy of Cancer 2021 Annual Meeting. "We are pleased to share preclinical data demonstrating the versatility of our Sleeping Beauty technology to develop neoantigen-specific TCR-T cells with the potential to address a wide range of solid tumor indications," commented Raffaele Baffa, M.D., Ph.D., Chief Medical Officer & EVP, Research & Development. "Our TCR-T library approach allows us to develop safe, effe
HOUSTON, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced financial results for the third quarter ended September 30, 2021 and provided a business update. "I am impressed by the quality and dedication of our team at Ziopharm who all are diligently working to transform our cutting-edge scientific research into meaningful clinical progress. Last quarter we made the decision to restructure the organization and focus our efforts on advancing our differentiated TCR-T library towards the clinic," said Kevin S. Boyle, Sr., Chief Executive Officer at Ziopharm Oncology. "We are making excellent progress to operationa
HOUSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced that it will report financial results for the third quarter ended September 30, 2021 on Monday, November 8, 2021, after the close of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 4:30 p.m. ET to provide a corporate update and review the financial results. The conference call can be accessed by dialing 877-451-6152 (United States) or 201-389-0879 (International) with the conference code 13724384. A live webcast may be accessed using the link here, or by visiting the "Investors" section of the Ziopharm website at w
• Over 50% reduction in personnel • Cost reductions expected to extend the cash runway into the first half of 2023 • The first patient in its TCR-T Library Phase I/II clinical trial is expected to be dosed in 1H2022 BOSTON and HOUSTON, Sept. 27, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced a restructuring enabling the company to advance its TCR program. Approximately 60 positions have been eliminated. The Company expects the changes will extend the cash runway into the first half of 2023. Kevin S. Boyle, Sr., Chief Executive Officer, said, "We appreciate the many contributions the impacted employees made to Ziopharm and w
BOSTON and HOUSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced that Kevin S. Boyle, Sr., Chief Executive Officer of Ziopharm, is scheduled to participate in five upcoming virtual investor conferences: 2021 Wells Fargo Virtual Healthcare ConferenceDate: September 9, 2021Presentation Time: 10:00 am EDT Morgan Stanley 19th Annual Global Healthcare ConferenceDate: September 10, 2021No presentation – management available for one-on-one meetings H.C. Wainwright 23rd Annual Global Investment ConferenceDate: September 13, 2021Time: 7:00 am EDT (access to on demand webcast begins) Lake Street 5th Annual Best
Mr. Boyle brings over 20 years of executive business leadership in CEO, CFO and operational leadership roles Strong track record of successfully guiding companies and creating shareholder value through disciplined capital management and achievement of milestones Raffaele Baffa MD, Ph.D. appointed Head of Research and Development in addition to Chief Medical Officer Adam Levy, Ph.D., MBA appointed Executive Vice President, Corporate Development and Investor Relations Conference call scheduled for today at 4:30 pm EDT BOSTON and HOUSTON, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today announced the appointment of Kevin S. Boyl
Accomplished key milestones in groundbreaking TCR-T Library program, including commissioning of Company's manufacturing facility and presentation of favorable preclinical data Closed venture debt financing with Silicon Valley Bank, strengthening balance sheet and extending cash runway into the fourth quarter of 2022 Provided update on CD19 RPM CAR-T trial being conducted by Eden BioCell Conference call scheduled for today at 4:30 pm EDT BOSTON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. ("Ziopharm" or the "Company") (NASDAQ:ZIOP), today provided corporate updates for the second quarter of 2021, ended June 30, 2021. The Company will host a conference call and webcast toda
BOSTON, July 26, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (NASDAQ:ZIOP), today announced that management will host a conference call and webcast on Monday, August 9, at 4:30 p.m. EDT to provide a corporate update and discuss financial results for the second quarter ended June 30, 2021. The conference call can be accessed by dialing 877-451-6152 (U.S. and Canada) or 201-389-0879 (International). The passcode for the conference call is 13721210. A live webcast may be accessed using the link here, or by visiting the "Investors" section of the Ziopharm website at www.ziopharm.com. The call will be recorded and available for replay on the Company's website for approximately 90 days aft
8-K - Alaunos Therapeutics, Inc. (0001107421) (Filer)
8-K - ZIOPHARM ONCOLOGY INC (0001107421) (Filer)
10-Q - ZIOPHARM ONCOLOGY INC (0001107421) (Filer)
8-K - ZIOPHARM ONCOLOGY INC (0001107421) (Filer)
8-K - ZIOPHARM ONCOLOGY INC (0001107421) (Filer)
8-K - ZIOPHARM ONCOLOGY INC (0001107421) (Filer)
8-K - ZIOPHARM ONCOLOGY INC (0001107421) (Filer)
10-Q - ZIOPHARM ONCOLOGY INC (0001107421) (Filer)
8-K - ZIOPHARM ONCOLOGY INC (0001107421) (Filer)
8-K - ZIOPHARM ONCOLOGY INC (0001107421) (Filer)
SHANGHAI and BOSTON, April 7, 2022 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T cell therapies for the treatment of hematologic malignancies and solid tumors, announces that Dr. Raffaele Baffa ("Dr. Baffa") has been appointed as the Chief Medical Officer ("CMO") of the Company, responsible for overseeing the global clinical development strategies and operations for the Company's innovative pipeline product candidates. Dr. Baffa will report to Dr. Zonghai Li, Founder, Chairman of the Board, CEO, CSO of CARsgen Therapeutics Holdings Limited. Dr. Baffa has rich experiences in pharmaceutical industry and research institutes,
– Mr. Huang is a veteran industry entrepreneur with 20+ years founding and funding biotech innovation – – Heidi Hagen elected Lead Independent Director – BOSTON, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or “the Company”) (Nasdaq: ZIOP) today announced the election of James Huang as Chairman of the Board of Directors (the “Board”), effective immediately. Mr. Huang has served on the Board since July 2020 and is currently a Managing Partner at Kleiner Perkins Caufield & Byers (KPCB) China. He has founded and financed several innovative life sciences companies, including GenScript, Legend Biotech and Zai Lab. He is also Founding Partner of Panacea Venture, which
Has Held Several Discussions with WaterMill to Reach an Amicable Resolution to Consent Solicitation Board Accepts Resignation of Director Elan Ezickson Reiterates Concerns About Professional Past of WaterMill Nominee Holger Weis BOSTON, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (Nasdaq: ZIOP) (“Ziopharm” or the “Company”), today announced that it has sent a letter to shareholders urging them to support the Company’s continued progress and long-term prospects. The letter was sent in connection with the Company’s definitive consent revocation statement in response to the consent solicitation initiated by WaterMill Asset
NEW YORK--(BUSINESS WIRE)--WaterMill Asset Management Corp. (together with its affiliates, “WaterMill” or “we”) today announced that Glass, Lewis & Co., LLC (“Glass Lewis”), a leading proxy advisory firm, has endorsed its case for meaningful change at Ziopharm Oncology, Inc. (NASDAQ: ZIOP) (“Ziopharm” or the “Company”) and recommended shareholders vote for all five proposals on WaterMill’s WHITE consent card. In particular, Glass Lewis supports the addition of the entire WaterMill slate – Robert Postma, Jaime Vieser and Holger Weis – to the Board of Directors (the “Board”). Glass Lewis also recommends that shareholders vote to remove four incumbents – Kevin Buchi, Elan Ezickson, Sco
4 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)
4 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)
3 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)
3 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)
4 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)
4 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)
4 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)
4 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)
4 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)
4 - ZIOPHARM ONCOLOGY INC (0001107421) (Issuer)
Ziopharm Ocology Inc (NASDAQ:ZIOP) has rebranded itself and has changed its name to Alaunos Therapeutics Inc. The Company will trade on NASDAQ under the new ticker symbol "TCRT" to be effective tomorrow. Along with the name change, the Company amended Phase 1/2 IND to add four additional T-cell receptors (TCRs) to its library, increasing the number of eligible patients for the clinical trial. Related: Ziopharm Shares Are Trading Lower After Slashing Workforce By Over 50%. Phase 1/2 TCR-T library trial targeting KRAS, TP53, and EGFR mutations across six solid tumor indications is open for enrollment at Texas' MD Anderson Cancer Center. Dosing is expected to start in 1H of 2022. Additi
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Gilead Hit With FDA Partial Clinical Hold On Multiple Blood Cancer Studies Evaluating Magrolimab-Vidaza Combo Gilead Sciences, Inc. (NASDAQ:GILD) said the U.S. Food and Drug Administration has placed a partial clinical hold on studies evaluating the combination of magrolimab plus Bristol-Myers Squibb Co's (NYSE:BMY) Vidaza due to an apparent imbalance in investigator-reported suspected unexpected serious adverse reactions between study arms. While no clear trend in the adverse reactions or new safety signal has been identified by Gilead at this time, the partial clinical hold is being implem
Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications is open for enrollment; continue to expect to dose the first patient in 1H 2022 Phase 1/2 IND amended to include four additional TCRs, bringing the total number of evaluable TCRs to 10, further expanding number of eligible patients In-house cGMP manufacturing facility is operational to support internal clinical development programs Company changes name to Alaunos Therapeutics reflecting renewed focus HOUSTON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Ziopharm Oncology, Inc. (“Ziopharm” or the “Company”) (NASDAQ:ZIOP), a clinical-stage oncology-focused cell therapy comp
During Friday's session, 445 companies made new 52-week lows. Noteable 52-Week Lows: Intuitive Surgical (NASDAQ:ISRG) is the largest company in terms of market cap to set a new 52-week low this morning. The company with the smallest market cap to set a new 52-week low was Antelope Enterprise Hldgs (NASDAQ:AEHL). CureVac (NASDAQ:CVAC) was the biggest loser of the morning session, as it dropped 10.02% to reach its new 52-week low. Staar Surgical (NASDAQ:STAA)'s shares had the biggest turnaround, impressively rebounding 0.0% after reaching a new 52-week low. Here is a list of stocks that set new 52-week lows on Friday: Snap (NYSE:SNAP) stock drifted down 1.72% on Friday morning t
Gainers GBS (NASDAQ:GBS) stock rose 14.28% to $1.44 during Friday's after-market session. At the close, GBS's trading volume reached 299.7K shares. This is 34.56% of its average volume over the last 100 days. The market value of their outstanding shares is at $21.4 million. Brickell Biotech (NASDAQ:BBI) shares moved upwards by 11.11% to $0.26. Trading volume for this security closed at 527.2K, accounting for 20.85% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $29.6 million. Zosano Pharma (NASDAQ:ZSAN) stock rose 6.66% to $0.54. Zosano Pharma's trading volume hit 130.4K shares by close, accounting for 5.99% of its average vo
Gainers ACADIA Pharmaceuticals (NASDAQ:ACAD) stock rose 24.26% to $24.11 during Monday's after-market session. Today's trading volume for this security ended up closing at 1.3 million shares, which is 106.1 percent of its average volume over the last 100 days. The company's market cap stands at $3.8 billion. Cumberland (NASDAQ:CPIX) stock increased by 8.64% to $7.54. At the close, Cumberland's trading volume reached 638.8K shares. This is 16.19% of its average volume over the last 100 days. The company's market cap stands at $111.6 million. Aptinyx (NASDAQ:APTX) stock moved upwards by 8.29% to $2.35. The market value of their outstanding shares is at $159.1 million. TherapeuticsMD (NASDA